Pharma Journalist -

SMi Reports: Alexander D. Graham’s interview released for SMi’s 3D Cell Culture Conference, taking place in February 2020 in London. In just under 4 weeks SMi’s 4th Annual 3D Cell…
Read More...

Roche announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab)…
Read More...

Bellicum Pharmaceuticals announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer Center will acquire Bellicum’s approximately…
Read More...

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two…
Read More...

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab…
Read More...

Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and…
Read More...

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now…
Read More...

SMi Reports: SMi’s Pharmaceutical Microbiology Conference series will feature an exciting agenda and expert speaker line-up. SMi Group are pleased to host the 3rd Annual…
Read More...